Efficacy of an online yoga-intervention in patients with a brain-derived tumor of WHO grades 3 & 4 and their caregivers.

Efficacy of an online yoga-intervention in patients with a brain-derived tumor of WHO grades 3 & 4 and their caregivers. - YINOTA-O

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00029554

Enrollment

140

Registered

2022-08-22

Start date

2024-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C71.9

Interventions

Group 1: After giving written consent to participate in the study, each participant receives the first set of questionnaires and an appointment for blood and hair sample collection. Subsequently, part

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnoses: disease of a brain-derived tumor WHO grades 3 & 4 (initial diagnosis and/or recurrent disease; 6 weeks after surgery at the earliest) (applies to patients only); Caregivers of a patient with a brain-derived tumor (WHO grades 3 & 4). Age = 18 years; regular access to a computer with internet access.

Exclusion criteria

Exclusion criteria: Insufficient German language skills; severe cognitive, affective or physical limitations

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the level of anxiety measured with the questionnaire for generalized anxiety disorder (GAD-7) before the start and after the end of the intervention as well as 3 months later. The primary endpoint is reached if the level of anxiety in the intervention group is significantly lower than in the waiting-list control group after the end of the intervention.	—

Secondary

Measure	Time frame
Secondary outcomes include progression anxiety (PA-F-KF), depression (PHQ-9), quality of life (EORTC QLQ-C30 + BN 20), BDNF, DHEA/DHEAS, ferritin, and hair cortisol. In addition, potential confounding factors are recorded: Sociodemographic data, general health data (patient only: type and stage of disease, time of diagnosis, treatment), current health data (patient only: current treatment and possible current changes in the course of the disease). All parameters (except sociodemographic data and general health data) will be collected before and after the intervention and 3 months after the end of the intervention. Sociodemographic data will be asked once at the first time point of the study and general health data will be taken from the electronic patient record at this time point of measurement by study staff.	—

Measure

Time frame

Secondary outcomes include progression anxiety (PA-F-KF), depression (PHQ-9), quality of life (EORTC QLQ-C30 + BN 20), BDNF, DHEA/DHEAS, ferritin, and hair cortisol. In addition, potential confounding factors are recorded: Sociodemographic data, general health data (patient only: type and stage of disease, time of diagnosis, treatment), current health data (patient only: current treatment and possible current changes in the course of the disease). All parameters (except sociodemographic data and general health data) will be collected before and after the intervention and 3 months after the end of the intervention. Sociodemographic data will be asked once at the first time point of the study and general health data will be taken from the electronic patient record at this time point of measurement by study staff.

—

Countries

Germany

Contacts

Public ContactElisabeth Jentschke

Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken, Psychoonkologie

jentschke_e@ukw.de0931 201 28889

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 5, 2026